Accelerating Drug Development by Operationalizing Patient Insights

Accelerating drug development is a universal priority for manufacturers. To increase speed without compromising quality, significant investments in new technologies, sometimes meaningful and sometimes trendy, are required. Yet, investments in gathering data from key stakeholders remain stagnant or are deprioritized when budgets are created. This is particularly true when evaluating patient engagement and insights gathering.

Yet, there is strong data that supports increasing this type of engagement. In 2020, The Economist published a report on the State of Patient Centricity that found 87 percent of patient-centric trials have positive results. Other research, such as that conducted at Tufts Center for the Study of Drug Development, reported that a single amendment in a typical Phase III protocol adds three months of unplanned time to a clinical trial.

This webinar will walk study sponsors through key principles to successful patient engagement and insights gathering while providing case studies that demonstrate the value of patient-focused drug development. The key topics will include the following:

• How to determine if an asset is viable in the current market
• How to identify potential areas of risk and develop mitigation strategies
• How to optimize study design and execution
• How to gain alignment on a successful study model
• How to optimize recruitment and retention strategies
• How to develop a successful value proposition
• How to prepare for successful commercialization

Register for this webinar today to learn how patient-focused drug development can drive efficiency, minimize delays and support a successful commercialization strategy.

Speaker

Devra Densmore, Founder and Principal Consultant, Elevate Advocacy

Devra Densmore began her patient advocacy journey at nine when she saw a news program highlighting the impact HIV/AIDS had on Ryan White. In the years that followed, she accelerated trial recruitment via equitable patient engagement; represented patients at the FDA; formed coalitions between advocacy groups to mobilize around legislative advocacy and built an advocacy function at multiple biotech companies.

After 20 years of strategic advocacy leadership, Devra formed Elevate Advocacy, a boutique consulting firm focused on providing differentiated patient engagement and advocacy counsel with a health equity lens. Her impact has been felt in over 25 rare and common disorders.

Message Presenter